A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.

A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015 May; 137(2):216-22.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Aged, 80 and over
Amyloid Precursor Protein Secretases
Benzazepines
Biomarkers, Tumor
California
Chicago
Disease-Free Survival
Enzyme Inhibitors
Female
Humans
Middle Aged
Neoplasms, Glandular and Epithelial
Neoplastic Stem Cells
Ontario
Ovarian Neoplasms
Receptors, Notch
Signal Transduction

authors with profiles

Gini Fleming